DeNovX an innovative pharmaceutical company that provides platform products for pharmaceutical and medical nutrition uses. Our pharmaceutical products division is advancing the development of a treatment for ulcerative colitis. Our pharmaceutical technology division is focused on the commercialization of products to accelerate pharmaceutical development while creating new intellectual property (IP) for commercially relevant products.
Looking for a particular DeNovX employee's phone or email?
The DeNovX annual revenue was $405000 in 2026.
Andrew Bond is the Co-Founder and Chief Operations Officer of DeNovX.
6 people are employed at DeNovX.
DeNovX is based in Chicago, Illinois.
The NAICS codes for DeNovX are [32541, 32, 325, 3254].
The SIC codes for DeNovX are [283, 28].